Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.

"Declarations Ethics approval and consent to participateAll animal procedures were approved by the Institutional Animal Care and Use Committee at The University of Texas MD Anderson Cancer Center. Consent for publicationAll co-authors have given their consent to the submitted version of the manuscript for publication. Competing interestsJ.W.W. is listed on a patent filed by MD Anderson regarding using mouse ASO for MER-TK treating cancer. J.W.W. is a co-founder of a company Oligo-Immune using ASO to macrophages targets including MER-TK for the treatment of pulmonary fibrosis. A.R., H.M., R.M. are employees of Ionis Pharmaceuticals Inc. Competing interests J.W.W. is listed on a patent filed by MD Anderson regarding using mouse ASO for MER-TK treating cancer. J.W.W. is a co-founder of a company Oligo-Immune using ASO to macrophages targets including MER-TK for the treatment of pulmonary fibrosis. A.R., H.M., R.M. are employees of Ionis Pharmaceuticals Inc."

"Funding This work was supported by Cancer Center Support (Core) Grant CA016672 to The University of Texas MD Anderson Cancer Center; the Goodwin family research fund; the family of M. Adnan Hamed and the Orr Family Foundation to MD Anderson Cancer Center’s Thoracic Radiation Oncology program; an MD Anderson Knowledge Gap award."